Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303602 · ClinicalTrials.gov registry record · Phase 4
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 149
- Enrollment target
NCT00303602: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00303602 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 149 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303602, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 149 participants
- Enrollment target
Study Summary
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already gaining weight on olanzapine.
Primary Outcome
Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of changes at various time points throughout the study. Change = Time point value minus baseline (Visit 2) value.
Interventions
- DRUG Sublingual orally disintegrating olanzapine (SODO)
- DRUG Oral olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
What the finished NCT00303602 record still lists
NCT00303602 is an interventional study that assigns participants to a tested intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Sublingual orally disintegrating olanzapine (SODO) is the first listed.
NCT00303602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00303602 about?
NCT00303602 is a clinical study titled "Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)". This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already gaining weight on olanzapine.
What is the current status of trial NCT00303602?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 149 participants. The study started on 2006-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00303602?
The interventions under investigation include: Sublingual orally disintegrating olanzapine (SODO) (DRUG), Oral olanzapine (DRUG).
Who is sponsoring clinical trial NCT00303602?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00303602's enrollment target sits among peer trials
149 565th of 2000 higher than 1,434 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia